M. Grubert

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

Heike Richly, Bernhard F. Henning, P. Kupsch et al. · Annals of Oncology · 2006 · 142 citations · Full text

Medicine, Pharmacology, Pathology +8

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial

Heike Richly, Beate Schultheis, Irenäus A. Adamietz et al. · European Journal of Cancer · 2008 · 83 citations

Oncology, Hepatology, Medicine +7

Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer

Heike Richly, P. Kupsch, K. J. Passage et al. · International Journal of Clinical Pharmacology and Therapeutics · 2004 · 51 citations

Hepatology, Medicine, Liver Physiology +8

Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors

Magdalena Henke, Heike Richly, A. Drescher et al. · International Journal of Clinical Pharmacology and Therapeutics · 2009 · 35 citations

Oncology, /-Indazole Hydrochloride, Medicine +8

Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis

Ralf A. Hilger, Heike Richly, M. Grubert et al. · International Journal of Clinical Pharmacology and Therapeutics · 2009 · 34 citations

Hemodialysis, Urology, Renal Function +8